Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Simbols: 300357.SZ
SHZ
25.97
CNYTirgus cena šodien
44.2441
P/E koeficients
-6.3048
PEG koeficients
13.60B
MRK Cap
- 0.01%
DIV ienesīgums
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357-SZ) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1288.8 | 1135.7 | 1020.9 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | 117.4 | 295.1 | 370.9 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 214.9 | 284.9 | 256.2 | |||||||||||||||
balance-sheet.row.inventory | 0 | 59 | 48.4 | 53.8 | |||||||||||||||
balance-sheet.row.other-current-assets | 0 | 7.2 | 8.1 | 10.7 | |||||||||||||||
balance-sheet.row.total-current-assets | 0 | 1569.9 | 1477.1 | 1341.5 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 704.8 | 444.6 | 301.6 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 0 | 188.4 | 189.5 | 176.4 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 188.4 | 189.5 | 176.4 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | -43.2 | -216.7 | -287.6 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 5 | 4.9 | 5.8 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 137.2 | 298.4 | 394.3 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 992.3 | 720.7 | 590.5 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 0 | 2562.2 | 2197.9 | 1932 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 8 | 7.7 | 5.1 | |||||||||||||||
balance-sheet.row.short-term-debt | 0 | 41.2 | 4 | 5.9 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 14.5 | 30.3 | 62.9 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 21.3 | 12.3 | 1.9 | |||||||||||||||
Deferred Revenue Non Current | 0 | 30.9 | 27.4 | 24.9 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 0 | 127.5 | 91.1 | 96.6 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 81.4 | 68 | 27.4 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 21.3 | 12.3 | 1.9 | |||||||||||||||
balance-sheet.row.total-liab | 0 | 258.5 | 170.8 | 135.4 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0 | 523.6 | 523.6 | 523.6 | |||||||||||||||
balance-sheet.row.retained-earnings | 0 | 1262.6 | 1092.7 | 889.6 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 270.7 | 235.1 | 194.7 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 128.2 | 128.2 | 128.2 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2185.1 | 1979.6 | 1736.1 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 2562.2 | 2197.9 | 1932 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 118.6 | 47.5 | 60.5 | |||||||||||||||
balance-sheet.row.total-equity | 0 | 2303.7 | 2027.1 | 1796.6 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||
Total Investments | 0 | 74.2 | 78.4 | 83.3 | |||||||||||||||
balance-sheet.row.total-debt | 0 | 62.4 | 16.3 | 7.8 | |||||||||||||||
balance-sheet.row.net-debt | 0 | -1108.9 | -824.4 | -642.2 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 295.5 | 335.7 | 326.3 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 38.5 | 26.1 | 25.1 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0.5 | -1 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | -0.5 | 1 | |||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 47.4 | -47.2 | 11.5 | |||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | -30.9 | -34.6 | |||||||||||||||
cash-flows.row.inventory | 0 | -9.4 | 4.1 | -5.4 | |||||||||||||||
cash-flows.row.account-payables | 0 | 0 | -20.9 | 52.5 | |||||||||||||||
cash-flows.row.other-working-capital | 0 | 56.8 | 0.5 | -1 | |||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 0.7 | 45.7 | -2.3 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -209.2 | -188.7 | -122.2 | |||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0.2 | 0 | |||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -600.1 | -484.4 | -843.1 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 612.2 | 517.6 | 742.7 | |||||||||||||||
cash-flows.row.other-investing-activites | 0 | 5.1 | 37.1 | 10.2 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -191.9 | -118.2 | -212.3 | |||||||||||||||
cash-flows.row.debt-repayment | 0 | -20 | -5.8 | -5.8 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | -105.6 | -105.2 | -83.8 | |||||||||||||||
cash-flows.row.other-financing-activites | 0 | 77.2 | 0 | 0 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -23.4 | -111 | -89.6 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 166.8 | 131.1 | 58.7 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 577.6 | 410.8 | 279.7 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 410.8 | 279.7 | 221 | |||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 382.1 | 360.3 | 360.6 | |||||||||||||||
cash-flows.row.capital-expenditure | 0 | -209.2 | -188.7 | -122.2 | |||||||||||||||
cash-flows.row.free-cash-flow | 0 | 172.9 | 171.5 | 238.4 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 848.2 | 896 | 807.7 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 40.2 | 41.3 | 34.4 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 808 | 854.7 | 773.3 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0 | 1 | 16.1 | 28.5 | |||||||||||||||
income-statement-row.row.operating-expenses | 0 | 494.2 | 439.5 | 407.2 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 534.4 | 480.8 | 441.6 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 31 | 24.8 | 22.6 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.4 | 0.4 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 1 | 2.5 | 0.1 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 1 | 16.1 | 28.5 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 1 | 2.5 | 0.1 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.4 | 0.4 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 38.5 | 75.9 | 27.2 | |||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 0 | 345 | 396.2 | 392.9 | |||||||||||||||
income-statement-row.row.income-before-tax | 0 | 346 | 398.7 | 393 | |||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 50.4 | 63 | 66.7 | |||||||||||||||
income-statement-row.row.net-income | 0 | 310.2 | 348.8 | 338 |
Biežāk uzdotie jautājumi
Kas ir Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) kopējie aktīvi?
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) kopējie aktīvi ir 2562166715.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.953.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 0.312.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.360.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.392.
Kāda ir Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 310184878.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 62443059.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 494184515.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.